Navigation Links
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
Date:7/20/2009

--- B (n=8) 50 mg/day -0.69 1 ------ ------------ ----- --- C (n=8) 75 mg/day -0.70 2 ------ ------------ ----- --- D (n=9) 100 mg/day -0.74 4 ------ ------------ ----- --- Control Placebo (n=8) +0.01 0 * Eight subjects were randomized to this cohort, two of whom were excluded from the viral load evaluation due to an error in dosing.

"We are pleased with the results of this study, which support the potential for IDX184 to be a best-in-class nucleoside/tide polymerase inhibitor with demonstrated antiviral activity and tolerability, coupled with a low once-daily dose," said Douglas Mayers, M.D., chief medical officer of Idenix. "Now that we have successfully completed the proof-of-concept study in HCV-infected patients, we plan to advance IDX184 into a 14-day dose-ranging study in combination with the current standard-of-care, pegylated interferon and ribavirin, to determine the optimal IDX184 doses to advance into broader clinical trials."

In the 75 and 100 mg/day cohorts, patients receiving IDX184 experienced improvements in two key markers of liver injury, with mean AST and ALT levels decreasing to below the upper limit of normal. These improvements were sustained for up to 6 days post-dosing, and most levels returned to baseline 14 days post-treatment.

"We have made great progress in our HCV discovery and development programs this year," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "With the successful completion of the proof-of-concept study for IDX184 and plans to file investigational new drug applications in the coming
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... LigoCyte Pharmaceuticals, Inc. , a private, clinical-stage ... vaccine products, announced today that it has initiated ... (IM) norovirus vaccine candidate, marking the fourth human ... (VLP) vaccine program.  The Phase I dose-escalation study ...
... Top researchers at the Gastrointestinal Cancer Research Lab at ... clinical applications of BCM-95®, a new patented extract of ... Previous studies have shown that BCM-95 curcumin was 7-10 ... had a retention time in the bloodstream between 8 ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2
(Date:4/18/2014)... A new study in the American Journal of ... searches reveals a recurring pattern that could be leveraged ... from San Diego State University, the Santa Fe Institute, ... Google searches (searches that included the term healthy and ... U.S. from 2005 to 2012. They found that on ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions ... an immune response to infection with malaria parasites that ... fever and illness and partially control the growth of ... researchers develop future interventions that prevent or mitigate the ... approximately 200 million cases of malaria occur worldwide, resulting ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Walter and Eliza Hall Institute scientists have revealed ... in the immune system, identifying in the process ... disorders. Dr Jeff Babon and Professor Nick ... and Haematology divisions respectively, study interactions between internal ...
... wallpaper-like liner help reduce the number of cases of malaria, ... Shepard, a professor at the Schneider Institutes for Health Policy ... gotten the Bill and Melinda Gates Foundation to help. A ... allow Shepard and collaborators to pursue their research in Kenya ...
... , THURSDAY, Feb. 16 (HealthDay News) -- Researchers have sequenced ... and the transmissible facial cancer that threatens the species with ... meat-eating marsupials found only on the Australian island of Tasmania, ... the journal Cell . "There are targeted drugs ...
... , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers have discovered ... of cases of inherited dilated cardiomyopathy, a serious heart muscle ... In the study, published in the Feb. 16 issue ... analyzed the DNA of 312 people with dilated cardiomyopathy, 231 ...
... parent-training program is effective in reducing the risk of low-income, ... found that after one year, there was a 9 percent ... group, while a control group that did not receive the ... obese children. "This is the first ...
... Reporter , WEDNESDAY, Feb. 15 (HealthDay News) -- Researchers report ... kicking off puberty in humans, a finding that offers insight ... who suffer from a rare disease that prevents the start ... family whose members have suffered from the disease confirmed that ...
Cached Medicine News:Health News:Cell signaling discovery provides new hope for blood disorders 2Health News:Gates Foundation awards grant to tackle malaria 2Health News:Genome Map Might Help Save Tasmanian Devil From Extinction 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 2Health News:Study Finds Gene Behind Inherited Cases of Enlarged Heart 3Health News:Parent-training intervention curbs pediatric obesity rates, study shows 2Health News:Parent-training intervention curbs pediatric obesity rates, study shows 3Health News:Gene Linked to Start of Puberty 2